期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

树突状细胞与肿瘤免疫治疗 被引量：1

下载PDF
导出
摘要 近年来,尽管由于手术、放疗、化疗技术的进步,一些恶性肿瘤仍不能得到痊愈.因此有必要探寻新的治疗策略,而抗肿瘤免疫治疗大有前景.其中,树突状细胞(Dendritic cells, DCs)在刺激初始免疫反应中起着极为重要的作用.特别是近几年体外大量扩增DCs技术的进展,使得以DCs为基础的肿瘤免疫治疗成为一大热点.
作者 李秋 魏于全
机构地区 四川大学华西医院肿瘤生物治疗中心
出处 《临床肿瘤学杂志》 CAS 2001年第3期280-282,共3页 Chinese Clinical Oncology
关键词 恶性肿瘤 树突状细胞 DCS 生物学特性 免疫疗法 肿瘤疫苗
分类号 R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1Hart DNJ, Hill GR. Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood, 1998, 90:3245-3287.
  • 2Tarte K, Klein B. Dendritic cell-based vaccine: A promising approach for cancer immunotherapy. Leukemia, 1999,13(5):653-663.
  • 3Sallusto F. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the MHC Ⅱ compartment: downregulation by cytokines and bacterial products. J Exp Med, 1995, 182:389-400.
  • 4Ridge JP. A conditional dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 1998, 393:474-478.
  • 5Almand B, Resser JR, Lindman B, et al. Clinical significance of defective cell differentiation in cancer. Clin Cancer Res, 2000,6(5):1755-1766.
  • 6Heiser A, Dahm P, R Yancey D, et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immumol, 2000,164(10):5508-5514.
  • 7Gong J, Avigan D, Chen D, et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc Natl Acad Sci USA, 2000,97(6):2715-2718.
  • 8Mclellan AD. Isolation of human blood dendritic cells by discontinuous Nycodenz gradient centrifugation. J Immunol Meth, 1995,184:81-89.
  • 9Miner BR. Cancer vaccines: Novel approaches and new promise. Pharmacol Ther, 1999, 81(2):121-139.
  • 10Chapuis Fl. Differentiatin of human dendritic cells from monocytes in vitro. Eur J Immunol, 1997, 27:431-441.

同被引文献20

  • 1黄兰青,张友会.肿瘤免疫治疗的新策略——肿瘤肽疫苗[J].国外医学（肿瘤学分册）,1996,23(2):92-96. 被引量：6
  • 2Machiel JP, Nicolas van Baren, Marchand M. Peptide-based cancer vaccines[J]. Seminars in Oncology,2002,29(5):494-502.
  • 3Colella TA, Timothy N, Bullock J, et al. Self-Tolerance to the murine homologue of a Tyrosinase-derived melanoma antigen: implications for tumor immunotherapy[ J]. J Exp Med, 2000,191 (7) : 1221-1232.
  • 4Wang F, Bade E, Kuniyoshi C ,et al. Phase. I clinical trial of a MART-1 peptede vaccine with incomplete freund's adjuvant for resected highrisk melanoma[J]. Clin Cancer Res, 1999,5 (10) : 2756-2765.
  • 5Marchand M, van Baren N, Rankin E, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide concoded by gene MAGE-3 and presented by HLA-A1 [ J ]. Int J Cancer, 1999,80(2) :219-230.
  • 6Valmori D, Dutoit V, Lienard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8^+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients [ J ]. Cancer Res, 2000, 60(16) :4499-4506.
  • 7Stockert E, Jager E, Chen TY, et al. A survey of the humoral response of cancer patient to a panel of human tumor antigens[J] .J Exp Med,1998,187(8) : 1349-1354.
  • 8Wang RF, Johnston SL, Zeng G, et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames [ J ]. The journal of Immunology, 1998,161(7) : 3596-3606.
  • 9Chantal B, Svetomir N, Esteban C. Chanllenges in the development of effective peptide vaccines for cancer [J ] .Mayo Clinic Proceedings,2002,77(4) :339-349.
  • 10Renner C, Trumper L, Pfreundschub M. Tumour vaccines : a new immunotherapeutic approach in oncology [J]. Ann Hemato, 2000,79 ( 12 ) :651-659.

引证文献1

临床肿瘤学杂志
2001年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部